ERBB2 and breast carcinoma: Current clinical management of breast cancer mainly depends on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) genes as molecular markers and therapeutic and prognostic indicators.